ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients
with prostate cancer with or without tumor in other parts of the body.
Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course)
or until evidence of progressive disease.